Suppr超能文献

造血干细胞和祖细胞动员的当前进展及其与骨髓生态位的相互作用

Current Developments in Mobilization of Hematopoietic Stem and Progenitor Cells and Their Interaction with Niches in Bone Marrow.

作者信息

Richter Rudolf, Forssmann Wolfgang, Henschler Reinhard

机构信息

Department of Internal Medicine, Clinic of Immunology, Hanover Medical School, Hanover, Germany.

MVZ Labor PD Dr. Volkmann & Kollegen, Karlsruhe, Germany.

出版信息

Transfus Med Hemother. 2017 Jun;44(3):151-164. doi: 10.1159/000477262. Epub 2017 May 29.

Abstract

The clinical application of hematopoietic stem and progenitor cells (HSPCs) has evolved from a highly experimental stage in the 1980s to a currently clinically established treatment for more than 20,000 patients annually who suffer from hematological malignancies and other severe diseases. Studies in numerous murine models have demonstrated that HSPCs reside in distinct niches within the bone marrow environment. Whereas transplanted HSPCs travel through the bloodstream and home to sites of hematopoiesis, HSPCs can be mobilized from these niches into the blood either physiologically or induced by pharmaceutical drugs. Firstly, this review aims to give a synopsis of milestones defining niches and mobilization pathways for HSPCs, including the identification of several cell types involved such as osteoblasts, adventitial reticular cells, endothelial cells, monocytic cells, and granulocytic cells. The main factors that anchor HSPCs in the niche, and/or induce their quiescence are vascular cell adhesion molecule(VCAM)-1, CD44, hematopoietic growth factors, e.g. stem cell factor (SCF) and FLT3 Ligand, chemokines including CXCL12, growth-regulated protein beta and IL-8, proteases, peptides, and other chemical transmitters such as nucleotides. In the second part of the review, we revise the current understanding of HSPC mobilization. Here, we discuss which mechanisms found to be active in HSPC mobilization correspond to the mechanisms relevant for HSPC interaction with niche cells, but also deal with other mediators and signals that target individual cell types and receptors to mobilize HSPCs. A multitude of questions remain to be addressed for a better understanding of HSPC biology and its implications for therapy, including more comprehensive concepts for regulatory circuits such as calcium homeostasis and parathormone, metabolic regulation such as by leptin, the significance of autonomic nervous system, the consequences of alteration of niches in aged patients, or the identification of more easily accessible markers to better predict the efficiency of HSPC mobilization.

摘要

造血干细胞和祖细胞(HSPCs)的临床应用已从20世纪80年代高度实验性的阶段发展到目前临床上已确立的治疗方法,每年有超过20000名患有血液系统恶性肿瘤和其他严重疾病的患者接受该治疗。众多小鼠模型研究表明,HSPCs存在于骨髓环境中的不同龛位。移植的HSPCs通过血液循环迁移并归巢到造血部位,而HSPCs可通过生理方式或药物诱导从这些龛位进入血液。首先,本综述旨在概述定义HSPCs龛位和动员途径的里程碑事件,包括识别涉及的几种细胞类型,如成骨细胞、外膜网状细胞、内皮细胞、单核细胞和粒细胞。将HSPCs锚定在龛位中,和/或诱导其静止的主要因素包括血管细胞黏附分子(VCAM)-1、CD44、造血生长因子,如干细胞因子(SCF)和FLT3配体、趋化因子,包括CXCL12、生长调节蛋白β和IL-8、蛋白酶、肽以及其他化学递质,如核苷酸。在综述的第二部分,我们修正了目前对HSPC动员的理解。在此,我们讨论在HSPC动员中发现的哪些机制与HSPC与龛位细胞相互作用的相关机制相对应,同时也探讨针对个体细胞类型和受体以动员HSPCs的其他介质和信号。为了更好地理解HSPC生物学及其对治疗的影响,仍有许多问题有待解决,包括钙稳态和甲状旁腺激素等调节回路的更全面概念、瘦素等代谢调节、自主神经系统的意义、老年患者龛位改变的后果,或者识别更容易获取的标志物以更好地预测HSPC动员的效率。

相似文献

5
Processing of CXCL12 by different osteoblast-secreted cathepsins.不同成骨细胞分泌的组织蛋白酶对 CXCL12 的加工。
Stem Cells Dev. 2012 Jul 20;21(11):1924-35. doi: 10.1089/scd.2011.0307. Epub 2012 Jan 4.
6
Neurological Regulation of the Bone Marrow Niche.神经对骨髓龛的调节作用。
Adv Exp Med Biol. 2020;1212:127-153. doi: 10.1007/5584_2019_398.

引用本文的文献

本文引用的文献

4
New agents in HSC mobilization.造血干细胞动员的新药物
Int J Hematol. 2017 Feb;105(2):141-152. doi: 10.1007/s12185-016-2156-2. Epub 2016 Nov 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验